BidaskClub upgraded shares of Simulations Plus (NASDAQ:SLP) from a buy rating to a strong-buy rating in a research report report published on Wednesday morning.

SLP has been the subject of a number of other research reports. Zacks Investment Research raised Simulations Plus from a hold rating to a buy rating and set a $20.00 target price for the company in a report on Saturday, July 21st. ValuEngine raised Simulations Plus from a buy rating to a strong-buy rating in a report on Monday, May 14th.

SLP stock opened at $19.25 on Wednesday. The stock has a market cap of $321.25 million, a price-to-earnings ratio of 56.62 and a beta of -0.85. Simulations Plus has a twelve month low of $14.00 and a twelve month high of $23.95.

Simulations Plus (NASDAQ:SLP) last posted its earnings results on Tuesday, July 10th. The technology company reported $0.13 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.12 by $0.01. The business had revenue of $8.55 million during the quarter, compared to analyst estimates of $7.86 million. Simulations Plus had a return on equity of 25.65% and a net margin of 29.88%. equities research analysts expect that Simulations Plus will post 0.4 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which was paid on Thursday, August 2nd. Stockholders of record on Thursday, July 26th were given a dividend of $0.06 per share. The ex-dividend date of this dividend was Wednesday, July 25th. This represents a $0.24 dividend on an annualized basis and a dividend yield of 1.25%. Simulations Plus’s dividend payout ratio (DPR) is presently 70.59%.

In other news, Director Walter S. Woltosz sold 18,500 shares of Simulations Plus stock in a transaction dated Friday, July 27th. The stock was sold at an average price of $17.76, for a total transaction of $328,560.00. Following the completion of the sale, the director now owns 5,454,908 shares in the company, valued at approximately $96,879,166.08. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 33.45% of the company’s stock.

Institutional investors and hedge funds have recently modified their holdings of the company. MetLife Investment Advisors LLC bought a new stake in shares of Simulations Plus during the 2nd quarter valued at about $129,000. Citigroup Inc. boosted its position in shares of Simulations Plus by 1,154.8% during the 1st quarter. Citigroup Inc. now owns 11,670 shares of the technology company’s stock valued at $172,000 after acquiring an additional 10,740 shares during the last quarter. Bank of Montreal Can bought a new stake in shares of Simulations Plus during the 2nd quarter valued at about $186,000. TIAA FSB bought a new stake in shares of Simulations Plus during the 2nd quarter valued at about $225,000. Finally, Acadian Asset Management LLC bought a new stake in shares of Simulations Plus during the 2nd quarter valued at about $233,000. Hedge funds and other institutional investors own 34.28% of the company’s stock.

Simulations Plus Company Profile

Simulations Plus, Inc develops drug discovery and development software for mechanistic modeling and simulation worldwide. The company offers GastroPlus, which simulates the absorption, pharmacokinetics (PK), and pharmacodynamics of drugs administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments, which measure the rate of dissolution of the drug and additives in a dosage form; and MembranePlus, which simulates laboratory experiments.

Further Reading: Price to Earnings Ratio (PE) Basics

Receive News & Ratings for Simulations Plus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Simulations Plus and related companies with MarketBeat.com's FREE daily email newsletter.